نتایج جستجو برای: ada recommendation

تعداد نتایج: 54271  

Journal: :Inflammatory bowel diseases 2012
Daniel A Sussman Nisa Kubiliun Parvez M Mulani Jingdong Chao Carol A T Gillis Mei Yang Mei Lu Maria T Abreu

BACKGROUND Anti-tumor necrosis factor (TNF) medications have similar efficacy in Crohn's disease (CD), but have not been compared in the real world. This study compared health costs and utilization for patients with CD newly initiating anti-TNF therapy with adalimumab (ADA) or infliximab (IFX) by using insurance data. METHODS CD patients initiating ADA or IFX therapy were identified from the ...

2012
Víctor Casanova Isaac Naval-Macabuhay Marta Massanella Marta Rodríguez-García Julià Blanco José M. Gatell Felipe García Teresa Gallart Carme Lluis Josefa Mallol Rafael Franco Núria Climent Peter J. McCormick

ADA is an enzyme implicated in purine metabolism, and is critical to ensure normal immune function. Its congenital deficit leads to severe combined immunodeficiency (SCID). ADA binding to adenosine receptors on dendritic cell surface enables T-cell costimulation through CD26 crosslinking, which enhances T-cell activation and proliferation. Despite a large body of work on the actions of the ecto...

2002
G. Gini

Robot programming languages are emerging from their experimental stage and entering an assessment phase. Their main features are illustrated and a parallel with ADA is proposed. The comparison is positive for ADA, in the sense that ADA provides most of the required capabilities. The ability of reasoning on object models and taking decisions will play an increasing role in the future. In this ca...

1999
Johann Blieberger Johann Klasek eva Kühn

CORSO, a coordination system for virtual shared memory, allows bindings to different programming languages. Currently C, C++, Java, VisualBasic, and Oracle’s Developer2000 are supported. We implement an Ada binding to CORSO, thus opening the area of virtual shared memory to the Ada world. Our Ada CORSO binding enhances Ada with transaction-oriented, fault-tolerant, distributed objects in a stra...

Journal: :QJM : monthly journal of the Association of Physicians 2014
C-W Yao B-R Wu K-Y Huang H-J Chen

BACKGROUND AND AIM The purpose of this study was to assess the relationship of pleural adenosine deaminase (P-ADA) and non-Hodgkin's lymphoma (NHL). DESIGN AND METHODS We retrospectively analysed 63 NHL patients with pleural effusions who accepted a diagnostic thoracentesis and who had P-ADA available at the China Medical University Hospital (Taichung, Taiwan) between January 2003 and April 2...

2013
Shintaro Hirata Kazuyoshi Saito Satoshi Kubo Shunsuke Fukuyo Yasushi Mizuno Shigeru Iwata Masao Nawata Norifumi Sawamukai Kazuhisa Nakano Kunihiro Yamaoka Yoshiya Tanaka

INTRODUCTION Evidences of biologics-free disease control after discontinuing adalimumab (ADA) in rheumatoid arthritis (RA) patients in clinical practice have not been sufficiently investigated. Purpose of this study is to investigate whether disease activity score 28 (DAS28)- erythrocyte sedimentation rate (ESR) remission was preserved after discontinuation of ADA in patients with RA. METHODS...

2008
Robert Stevens

The GRASP/Ada project (Graphical Representations of Algorithms, Structures, and Processes for Ada) has successfully created and prototyped an algorithmic level graphical representation for Ada software, the Control Structure Diagram (CSD), and a new visualization for a fine-grained complexity metric called the Complexity Profile Graph (CPG). By synchronizing the CSD and the CPG, the CSD view of...

2016
Kittipong Maneechotesuwan Kanda Kasetsinsombat Adisak Wongkajornsilp Peter J. Barnes

BACKGROUND Adenosine deaminase (ADA) and osteopontin (OPN) may play opposing roles in the pathogenesis of COPD. Deficiency of ADA results in enhanced adenosine signaling which up-regulates OPN expression. Although statins suppress OPN in cancer cells, little is known about their effects on ADA and OPN in COPD patients. METHODS We extended a previous randomized double-blind placebo crossover s...

2018
Michael E. Weinblatt Asta Baranauskaite Jaroslaw Niebrzydowski Eva Dokoupilova Agnieszka Zielinska Janusz Jaworski Artur Racewicz Margarita Pileckyte Krystyna Jedrychowicz‐Rosiak Soo Yeon Cheong Jeehoon Ghil S. Sokolovic M. Mekic N. Prodanovic B. Gajic E. Karaselimovic‐Dzambasovic B. Pojskic A. Toncheva P. Dimitar L. Rodina M. Geneva‐Popova I. Staykov R. Stoilov L. Podrazilova Z. Mosterova G. Simkova J. Kopackova Z. Stejfova J. Vencovsky Z. Urbanova L. Janska D. Galatíkova S. Stropuviene I. Sniuoliene K. Sitek‐Ziolkowska M. Rell‐Bakalarska R. Kolasa S. Daniluk B. Sliwowska M. Bartosik‐Twardowska J. Brzezicki M. Konieczny S. Jeka J. Choe S. Bae Y. Kang L. Prystupa Z. Vyacheslav I. Gasanov R. Yatsyshyn D. Rekalov O. Iaremenko M. Stanislavchuk V. Tseluyko

OBJECTIVE SB5 is a biosimilar agent for adalimumab (ADA). The aim of this study was to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity of SB5 in comparison with reference ADA in patients with rheumatoid arthritis (RA). METHODS In this phase III, randomized, double-blind, parallel-group study, patients with moderately to severely active RA despite treatment with methot...

2011
Jae-Geun Lee Dong Gu Kang Jung Re Yu Youngree Kim Jinsoek Kim Gwanpyo Koh Daeho Lee

BACKGROUND Dipeptidyl peptidase 4 (DPP-4, also known as CD26) binds with adenosine deaminase (ADA) to activate T lymphocytes. Here, we investigated whether ADA activity is specifically affected by treatment with DPP-4 inhibitor (DPP4I) compared with other anti-diabetic agents. METHODS Fasting ADA activity, in addition to various metabolic and biochemical parameters, were measured in 262 type ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید